LACTOLOGY FOUNDATION

Diastase (ATC A09AA01): Toxicological and Lactation Monograph

ATC Class and General Pharmacology

Diastase is classified in the World Health Organization Anatomical Therapeutic Chemical system as A09AA01, within:

• A — Alimentary Tract and Metabolism
• A09 — Digestives, including enzymes
• A09AA — Enzyme preparations
• A09AA01 — Diastase

The A09AA subgroup is restricted to enzymes used for digestive disorders. Diastase is therefore classified as an oral digestive enzyme rather than as a systemic enzyme medicine.atcddd.fhi

Diastase is a general term historically used for preparations with predominantly amylolytic activity. In pharmaceutical practice, it commonly refers to alpha-amylase-containing preparations, often fungal diastase derived from Aspergillus oryzae, although the exact biological source, enzymatic activity, purity, and accompanying ingredients may vary substantially between products and jurisdictions.pmc.ncbi.nlm.nih

Its principal pharmacological action occurs locally in the gastrointestinal lumen. Diastase catalyses the hydrolysis of dietary starch and related polysaccharides into smaller carbohydrate fragments, including dextrins and sugars that can undergo further digestion and absorption. It is intended to support carbohydrate digestion in selected states of dyspepsia, digestive discomfort, impaired digestive capacity, or reduced endogenous enzyme activity.

Diastase is frequently marketed in combination products. These may include proteolytic enzymes, acidifying agents, anti-foaming agents, carminatives, probiotics, or other ingredients. Such combinations must not be assessed as if they were diastase alone: the lactation and toxicological profile of the complete formulation depends on every active substance and excipient present.

The medicine’s activity is highly dependent on the gastrointestinal environment. Gastric acidity, food intake, dosage form, concomitant antacids, and the presence of other digestive enzymes may influence its functional activity. As an enzyme preparation, diastase has no intended central nervous system, cardiovascular, endocrine, or systemic pharmacodynamic effect.

Toxicological Profile

The toxicological profile of orally administered diastase is generally characterized by low expected systemic exposure and predominantly local gastrointestinal effects. As a proteinaceous enzyme preparation, diastase is expected to act within the gastrointestinal tract and to be degraded or inactivated through normal digestive processes. Intact absorption into the maternal circulation is expected to be limited under usual conditions of oral use.

Most adverse effects, when they occur, are likely to be mild and gastrointestinal. Possible reactions include:

• Abdominal discomfort or cramping
• Nausea
• Bloating, flatulence, or dyspepsia
• Loose stools or diarrhoea
• Less commonly, constipation or vomiting
• Local intolerance related to the product’s excipients or accompanying active ingredients

Hypersensitivity is a relevant, though uncommon, toxicological concern. Fungal diastase preparations may contain enzyme material obtained from microbial sources such as Aspergillus oryzae. A patient with known allergy to fungal enzymes, mould-related materials, or a specific formulation component should avoid use unless specialist assessment supports treatment. Allergic manifestations may include rash, pruritus, urticaria, facial swelling, wheeze, or other symptoms of immediate hypersensitivity.

Diastase should not be considered a treatment for undiagnosed or persistent gastrointestinal symptoms. Recurrent indigestion, chronic abdominal pain, dysphagia, weight loss, gastrointestinal bleeding, persistent vomiting, severe diarrhoea, or altered bowel habit may indicate an underlying disorder requiring medical assessment. Enzyme supplementation may mask symptoms temporarily without addressing the cause.

Toxicological assessment must also distinguish licensed medicinal preparations from food supplements. Non-prescription digestive-enzyme products may vary in enzyme potency, declared activity, microbial source, purity, formulation quality, accompanying herbal ingredients, and regulatory oversight. These variables are particularly important during lactation, when avoidable maternal exposure to poorly characterized ingredients should be minimized.

Lactation Pharmacology and Infant Exposure

Direct, product-specific human milk concentration data for diastase are limited. This evidentiary limitation should be stated clearly: an absence of published milk-transfer studies is not equivalent to proof of safety. Nevertheless, the pharmacological characteristics of diastase make clinically significant transfer into breast milk unlikely in usual circumstances.

Diastase is an orally administered digestive enzyme with mainly local gastrointestinal action. Its intact systemic absorption in the mother is expected to be low because it is a relatively large proteinaceous molecule subject to degradation in the gastrointestinal tract. Consequently, the amount available in maternal plasma for transfer into milk is likely to be minimal.

If very small quantities of enzyme-derived material were present in milk, the breastfed infant would be expected to digest the protein in the gastrointestinal tract. This further reduces the biological plausibility of clinically meaningful systemic infant exposure. On pharmacokinetic grounds, the risk of pharmacological effects in the infant from maternal use of diastase alone is therefore expected to be low.

However, several practical qualifications are important:

• Diastase is not always supplied as a single-ingredient product.
• Combination products may contain pepsin, acids, simethicone, herbal extracts, probiotics, sugar alcohols, alcohol-containing vehicles, flavourings, or other active ingredients.
• The source of the diastase enzyme may differ among products.
• Oral syrups and supplements can contain substantial amounts of sugars, ethanol, or other excipients that require individual review.
• Published lactation data remain insufficient to make a universal evidence-based statement for every diastase formulation.

There is no clinical rationale to expect maternal diastase therapy to alter milk production, milk composition, or infant carbohydrate metabolism through pharmacological transfer. However, significant maternal gastrointestinal disease, poor oral intake, dehydration, malabsorption, or inadequate nutrition may indirectly affect maternal wellbeing and breastfeeding success. These clinical issues should be managed independently of the enzyme product itself.

Lactological Safety Assessment and Clinical Recommendations

Diastase used as a single-ingredient oral digestive enzyme is likely to present a low lactation risk when used at standard therapeutic doses. Its local gastrointestinal mechanism, expected minimal maternal absorption, and probable digestion of any trace protein material by the infant support compatibility with breastfeeding on pharmacological grounds. This assessment is necessarily cautious because direct human lactation studies for diastase are limited.

Breastfeeding interruption or routine milk disposal is not generally expected to be necessary when a lactating mother uses a conventional, well-characterized diastase preparation for a clear clinical indication. The maternal benefit should be assessed in relation to the reason for treatment. If symptoms are mild and self-limiting, non-pharmacological measures or medical evaluation of the underlying cause may be preferable to prolonged empirical digestive-enzyme use.

Clinical recommendations

• Prefer a single-ingredient, regulated medicinal product when diastase is clinically indicated during breastfeeding.
• Confirm the exact formulation before making a lactation decision, especially for products marketed as “digestive enzyme,” “fungal diastase,” or “diastase complex.”
• Assess all co-formulated active substances separately; the lactation conclusion for diastase cannot automatically be applied to pepsin, acidifying agents, herbal compounds, probiotics, antifoaming agents, or alcohol-containing syrup vehicles.
• Use the lowest effective dose for the shortest appropriate period unless ongoing replacement therapy is clinically justified.
• Avoid poorly standardized supplements with uncertain enzyme activity, unclear microbial source, undeclared additives, or non-transparent manufacturing information.
• Avoid treatment in women with known hypersensitivity to diastase, fungal-derived enzyme products, or relevant formulation ingredients.
• Investigate persistent, severe, recurrent, or alarm-feature gastrointestinal symptoms rather than relying on repeated symptomatic self-treatment.
• Obtain individualized advice for mothers of premature, medically unstable, or highly allergy-prone infants, although clinically significant exposure is still not expected from diastase alone.

Infant monitoring

No special infant monitoring is generally required when the mother uses a conventional diastase-only product and the infant is healthy and full term. As a precaution, caregivers may observe for unusual gastrointestinal symptoms or possible hypersensitivity manifestations, including persistent diarrhoea, vomiting, rash, wheeze, marked feeding difficulty, or unexpected poor weight gain.

Such events would not necessarily be caused by maternal diastase use and should prompt clinical evaluation for more likely infant, dietary, infectious, allergic, or gastrointestinal causes. If an infant develops a plausible temporally related reaction, the maternal product should be reviewed in detail, including all accompanying active ingredients and excipients.

Overall conclusion

Diastase (A09AA01) is an oral amylolytic digestive enzyme preparation used to support carbohydrate digestion. It acts principally in the maternal gastrointestinal tract and is expected to have limited intact systemic absorption. Therefore, clinically important passage into breast milk and pharmacological exposure of the breastfed infant are unlikely.atcddd.fhi+1

For a standard single-ingredient diastase preparation, breastfeeding can usually continue. The principal clinical caveat is not diastase itself, but the frequent presence of additional ingredients in combination products and supplements. A product-specific review remains appropriate whenever the formulation is complex, the dose is unusually high, the medicine is non-standardized, or the infant is premature or medically vulnerable.